ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CTSO CytoSorbents Corporation

0.82
-0.0017 (-0.21%)
Last Updated: 11:01:38
Delayed by 15 minutes

Period:

Draw Mode:

Volume 6,626
Bid Price 0.82
Ask Price 0.863
News -
Day High 0.8471

Low
0.782

52 Week Range

High
4.29

Day Low 0.82
Company Name Stock Ticker Symbol Market Type
CytoSorbents Corporation CTSO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0017 -0.21% 0.82 11:01:38
Open Price Low Price High Price Close Price Prev Close
0.8302 0.82 0.8471 0.8217
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
29 6,626 $ 0.8295818 $ 5,497 - 0.782 - 4.29
Last Trade Time Type Quantity Stock Price Currency
11:01:38 300 $ 0.82 USD

CytoSorbents Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
36.88M 44.44M - 36.35M -28.51M -0.64 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CytoSorbents News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CTSO Message Board. Create One! See More Posts on CTSO Message Board See More Message Board Posts

Historical CTSO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.810.920.78990.8254934107,0470.011.23%
1 Month0.911.020.7820.892963997,833-0.09-9.89%
3 Months1.001.060.7820.9431803101,609-0.18-18.00%
6 Months1.902.150.7821.13231,905-1.08-56.84%
1 Year2.724.290.7821.51149,561-1.90-69.85%
3 Years9.179.800.7823.73189,194-8.35-91.06%
5 Years6.9313.890.7826.05269,054-6.11-88.17%

CytoSorbents Description

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.

Your Recent History

Delayed Upgrade Clock